EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K/AKT/mTOR pathway

Chunyan Wu, Shilv Chen, Zhimin Wu, Jiao Xue, Wen Zhang, Shan Wang, Xindong Zhao, Shaoling Wu

Journal of Cancer Research and Clinical Oncology · 2024

DOI: 10.1007/s00432-024-05615-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von Chunyan Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, 266003, Shandong, China. Hauptthemen laut MEDLINE: Phosphatidylinositol 3-Kinases, Lymphoma, Large B-Cell, Diffuse, Aminopyridines, Benzamides. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The initial therapeutic approach for diffuse large B-cell lymphoma (DLBCL) entails a rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen. However, 40% of patients exhibit suboptimal responses, with some experiencing relapse and refractory conditions. This study aimed to explore novel therapeutic strategies and elucidate their underlying mechanisms in DLBCL.

Methods

Bioinformatics techniques were employed to scrutinize correlations between the HDAC1, HDAC2, HDAC3, HDAC10, BTK, MYC, TP53, and BCL2 genes in DLBCL. In vitro experiments were conducted using DB and SU-DHL-4 cells treated with chidamide, orelabrutinib, and a combination of both. Cell viability was assessed by cell counting kit-8. Cell apoptosis and the cell cycle were determined using flow cytometry. Reactive oxygen species (ROS) production and mitochondrial function were assessed through ROS and JC-1 staining. RNA sequencing and western blot analyses were conducted to elucidate the molecular mechanisms underlying the combined action of chidamide and orelabrutinib in DLBCL cells.

Results

This investigation revealed markedly enhanced antiproliferative effects when chidamide was combined with orelabrutinib. Compusyn software analysis indicated a synergistic effect of chidamide and orelabrutinib in inhibiting DLBCL cell proliferation, with a combination index (CI) < 1. This synergy further manifested as augmented cell cycle arrest, apoptosis induction, the downregulation of cell cycle-associated and antiapoptotic proteins, and the upregulation of proapoptotic proteins. Furthermore, the western blot and RNA-Seq findings suggested that combining chidamide and orelabrutinib modulated the PI3K/AKT/mTOR signaling pathway, thereby promoting DLBCL cell cycle arrest and apoptosis.

Conclusion

The findings of this study provide a compelling justification for the clinical utilization of chidamide and orelabrutinib to treat relapsed/refractory DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphatidylinositol 3-KinasesLymphoma, Large B-Cell, DiffuseAminopyridinesBenzamidesPiperidinesPyridinesHumansProto-Oncogene Proteins c-aktReactive Oxygen SpeciesNeoplasm Recurrence, LocalApoptosisCell Cycle CheckpointsTOR Serine-Threonine KinasesHistone Deacetylases

Stichwörter der Autor:innen

ApoptosisCell cycle arrestChidamideDiffuse large B-cell lymphomaOrelabrutinibPI3K/AKT/mTOR pathway

Substanzen

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamidePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktorelabrutinibReactive Oxygen SpeciesTOR Serine-Threonine KinasesHDAC10 protein, humanHistone DeacetylasesAminopyridinesBenzamides

Autor:innen und Institutionen

  • Department of Hematology, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, 266003, Shandong, China.
  • Department of Medicine, Qingdao University, Qingdao, China.
  • Department of Hematology, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, 266003, Shandong, China. qdwushaoling@163.com.

Förderung

  • Natural Science Foundation of Shandong Province

Zitieren

APA

Wu, C., Chen, S., Wu, Z., Xue, J., Zhang, W., Wang, S., Xindong Zhao, & Wu, S. (2024). Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K/AKT/mTOR pathway. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05615-7

Vancouver

Wu C, Chen S, Wu Z, Xue J, Zhang W, Wang S, et al. Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K/AKT/mTOR pathway. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05615-7

BibTeX
@article{Wu2024,
  author = {Wu, Chunyan and Chen, Shilv and Wu, Zhimin and Xue, Jiao and Zhang, Wen and Wang, Shan and Xindong Zhao and Wu, Shaoling},
  title = {Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K/AKT/mTOR pathway},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  doi = {10.1007/s00432-024-05615-7}
}
Kostenlos starten →